SCHEMBL491187

SCHEMBL491187

COc1ccc(OC)c(C(C)C(=O)O)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 4/20 0.61
PTGS1 P23219 3/20 0.61
AKR1C3 P42330 2/20 0.57
AKR1C2 P52895 2/20 0.57
CYP2D6 P10635 2/20 0.57
ADRA2A P08913 2/20 0.57
ADRA1A P35348 2/20 0.57
CDC42 P60953 1/20 0.57
RAC1 P63000 1/20 0.57
CYP1A2 P05177 1/20 0.57
TSHR P16473 1/20 0.57
SLC22A6 Q4U2R8 1/20 0.57
MEN1 O00255 1/20 0.55
MAPK1 P28482 1/20 0.55
BLM P54132 1/20 0.55
KMT2A Q03164 1/20 0.55
HTT P42858 1/20 0.54
ADRB2 P07550 1/20 0.51
ADRB1 P08588 1/20 0.51
ADRB3 P13945 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31512445 1.00 PTGS2 (0.61) PTGS2PTGS1AKR1C3AKR1C2CYP2D6
SCHEMBL28027161 0.88 ADRA1A (0.58) PTGS2PTGS1CYP2D6ADRA2AADRA1A
SCHEMBL30946604 0.86 PTGS2 (0.57) PTGS2PTGS1AKR1C3AKR1C2CDC42
SCHEMBL490635 0.86 PTGS2 (0.57) PTGS2PTGS1AKR1C3AKR1C2CDC42
SCHEMBL4981399 0.85 CYP2D6 (0.58) CYP2D6ADRA2AADRA1ACYP1A2TSHR
SCHEMBL3660477 0.83 ADRA1A (0.54) PTGS2PTGS1AKR1C3AKR1C2CYP2D6
SCHEMBL6372641 0.83 PTGS2 (0.57) PTGS2PTGS1AKR1C3AKR1C2CDC42
SCHEMBL28936060 0.82 ADRA1A (0.65) PTGS2PTGS1AKR1C3AKR1C2CYP2D6
SCHEMBL8638138 0.82 CYP2D6 (0.53) PTGS2PTGS1CYP2D6ADRA2AADRA1A
SCHEMBL23414454 0.81 ADRA1A (0.59) CYP2D6ADRA2AADRA1ACYP1A2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107303298-B Pharmaceutical application of benzo [ g ] heteroaryl [ a, g ] quinolizine compound and preparation method thereof 中国科学院上海药物研究所 2021-06-22 CN disclosed
CN-102295549-B Benzindene triptycene and spirofluorene-benzindene triptycene derivative and preparation method thereof UNIV EAST CHINA NORMAL 2013-06-19 CN disclosed
US-8268293-B2 Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives MERCK PATENT GMBH (DE) 2012-09-18 US disclosed
CN-101163659-B Antioxidants MERCK PATENT GMBH 2012-09-05 CN disclosed
US-8106233-B2 Applying di-2-ethylhexyl 4-hydroxy-3,5-dimethoxy-benzylmalonate; protective action against UV rays, oxidative stress on body cells, counters skin ageing MERCK PATENT GMBH (DE) 2012-01-31 US disclosed
CN-102295549-A Benzindene triptycene and spirofluorene-benzindene triptycene derivative and preparation method thereof 2011-12-28 CN disclosed
US-20080171004-A1 Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives MERCK PATENT GMBH (DE) 2008-07-17 US disclosed
US-20080152603-A1 Antioxidants SUSONITY Commercial GmbH (DE) 2008-06-26 US disclosed
CN-101203278-A Ultraviolet protection MERCK PATENT GMBH (DE) 2008-06-18 CN disclosed
CN-101163659-A Antioxidants MERCK PATENT GMBH (DE) 2008-04-16 CN disclosed
EP-1871339-A1 UV PROTECTION Merck Patent GmbH (DE) 2008-01-02 EP disclosed
EP-1871735-A1 ANTIOXIDANTS Merck Patent GmbH (DE) 2008-01-02 EP disclosed
WO-2006111233-A1 ANTIOXIDANTS MERCK PATENT GMBH (DE) 2006-10-26 WO disclosed
WO-2006111234-A1 UV PROTECTION MERCK PATENT GMBH (DE) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080152603-A1 Antioxidants GPX4, GPX1, CAT PTGS2 320/4885PTGS1 262/4885AKR1C3 289/4885
US-20080171004-A1 Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives HPD, HAAO, UGT1A6 PTGS2 1873/4885PTGS1 1937/4885AKR1C3 733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.